SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica 600x60px
Document › Details

Denali Therapeutics Inc.. (11/8/18). "Press Release: Denali Therapeutics Reports Third Quarter 2018 Financial Results and Business Highlights and Announces the Appointment of Jennifer Cook to Board of Directors". South San Francisco, CA.

Organisations Organisation Denali Therapeutics Inc. (Nasdaq: DNLI)
  Group Denali Therapeutics (Group)
  Organisation 2 Genzyme Corporation
  Group Sanofi (Group) [since May 2011]
Products Product RIPK1 inhibitor (receptor-interacting serine/threonine-protein kinase 1 inhibitor)
  Product 2 DNL747 (Denali / Sanofi)
Index term Index term Sanofi–Denali Therapeutics: RIPK1 inhibitors, 201811– collab $125m upfront + >$1b + royalties RIPK1 inhibitors incl DNL 747 + DNL 758
Person Person Watts, Ryan (Denali Therapeutics 201608 CEO)

Record changed: 2018-11-16


Picture [LSUS] – The Business Web Portal 600x60px

More documents for Denali Therapeutics (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [LSG] – The Business Web Portal 600x80px

» top